BashTheBug and COVID-19 Philip Fowler, 12th April 202027th September 2021 Like many of you, the researchers behind BashTheBug have been at home for a while now due to restrictions put in place to slow the progress of this COVID-19 epidemic. There are not very many infectious disease Citizen Science projects and naturally we’ve given a lot of thought as to how we might help, but have come to the conclusion that (i) there is no compelling way a Zooniverse project could help with the epidemic, at the present time at least, and (ii) the work you all helping us fight tuberculosis by improving genetics-based diagnosis is hugely important. Let’s put it into context: the World Health Organisation estimated that around 10 million people fell ill with tuberculosis in 2018 and around 1.5 million died. At the time of writing, whilst no-one knows how many people will ultimately die as a result of being infected by this new virus, the current number was still more than 10x fewer than the number that will likely die of tuberculosis, which is treatable, during this year. So please keep classifying and if we do find a way to help, we’ll let you all know. Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Related BashTheBug on the Zooniverse News
Major five-year project awarded 18th November 202418th November 2024 One side of research that isn’t seen much but is hugely important is securing the… Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Read More
Read about tuberculosis and CRyPTIC in the Economist 20th October 2021 Hot on the heels of the press release, the Economist have published an article describing the work of… Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Read More
BashTheBug on the Zooniverse Google 11th December 201727th September 2021 Last week, BashTheBug was invited to Google in London to celebrate winning the Community Award… Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Read More